<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">In drug development, extensive preclinical studies are universally required to generate sufficient data regarding feasibility, safety, and efficacy, before launching clinical trials. However, this classical approach is not applicable for combating COVID-19 [
 <xref rid="bb0005" ref-type="bibr">1</xref>], because it is a new disease that only emerged in December 2019 and has already evolved into a global pandemic with an urgent and unmet clinical need. Current studies are mainly based on repurposing existing approved drugs or pipeline compounds. These agents have been shown to be effective in other disease indications that appear to share some similar pathophysiological pathways with COVID-19, and a few may have some evidence from cell culture models showing inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [
 <xref rid="bb0010" ref-type="bibr">2</xref>], the causative agent of COVID-19.
</p>
